LRPAP1 and atherosclerosis: To summarize, this study presents a facile‐manufactured DNA‐based nanoformulation for simultaneous delivery of RAP and LOX‐1 blockers with good biosafety, specific plaque targeting, and promoted anti‐atherosclerosis efficiency, providing a promising delivery platform for plaque‐targeted drug delivery and synergistic AS therapy.